Lenze, 152 patient fluvoxamine early treatment RCT: 93% lower progression [p=0.009] and 82% lower hospitalization [p=0.009] https://c19p.org/lenze
copied to clipboard
Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial
et al., JAMA, doi:10.1001/jama.2020.22760, NCT04342663 (history)
RCT 152 outpatients, 80 treated with fluvoxamine showing lower progression with treatment (0 of 80 versus 6 of 72 control). STOP COVID trial. NCT04342663 (history).
|
risk of progression, 92.7% lower, RR 0.07, p = 0.009, treatment 0 of 80 (0.0%), control 6 of 72 (8.3%), NNT 12, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), clinical deterioration over 15 days.
|
|
risk of hospitalization, 82.0% lower, RR 0.18, p = 0.009, treatment 1 of 80 (1.2%), control 5 of 72 (6.9%), NNT 18, COVID-19 hospitalization within 15 days, see supplemental appendix for details.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Lenze et al., 12 Nov 2020, Double Blind Randomized Controlled Trial, USA, peer-reviewed, 11 authors, average treatment delay 4.0 days, trial NCT04342663 (history).
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.